雷珠单抗玻璃体注射联合激光治疗视网膜大动脉瘤

Intravitreous injection of Lucentis combined with argon laser photocoagulation for treatment of retinal macroaneurysm

目的:研究雷珠单抗玻璃体腔内注射联合激光治疗视网膜大动脉瘤的临床疗效。方法:回顾性分析2011-01/2013-07就诊于我院眼科确诊的视网膜大动脉瘤伴发黄斑水肿9例9眼患者行雷珠单抗玻璃体腔内注射联合视网膜光凝治疗。观察治疗前和治疗后1,3mo患者的最佳矫正视力、眼底动脉瘤的变化情况及黄斑水肿的消退情况,进行统计学分析。结果:治疗后大于3mo的随诊观察,所有患者的最佳矫正视力均有明显提高,与治疗前相比,差异有统计学意义(P<0.05);OCT检测的黄斑中心凹厚度,治疗后较治疗前变薄,差异有统计学意义(P<0.05)。治疗后3mo眼底荧光血管造影检查显示:动脉瘤均有不同程度的萎缩和变小。结论:雷珠单抗玻璃体腔内注射联合视网膜光凝治疗伴发黄斑水肿的视网膜大动脉瘤安全、有效。

AIM： To evaluate the clinical efficacy of intravitreous injection of Lucentis combined with argon laser photocoagulation on retinal macroaneurysm. METHODS： A retrospective observation about intravitreous injection of Lucentis combined with argon laser photocoagulation was performed on 9 patients （ 9 eyes） with retinal macroaneurysms with macular edema between January 2011 and July 2013. Through the collection of clinical data in patients best-corrected visual acuity, change of the retinal macroaneurysm, optical coherence tomography and fluoresce in fundus angiography before therapy and 1 mouth,3 mouths after therapy, comparative analysis the changes in best -corrected visual acuity and central macular retinal thickness （ CMT） between before and after treatment. RESULTS： Followed for more than 3 months, all patients＆#39; best- corrected visual acuity were improved obviously, the difference was significant（P〈0. 05）; The patients＇ macular edema was obviously absorbed and the＆amp;nbsp;average CMT was significantly lower, the difference was significant（P〈0. 05）. In fundus fluorescein angiography, the neoplasia body was atrophied inordinately after 3 months of treatment. CONCLUSION： Intravitreous injection of Lucentis combined with argon laser photocoagulation is effective and security to improving visual acuity of retinal macroaneurysms with macular edema.